ReviewCancers2021
Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Pooled it
- Prognostic Significance and Clinical Implications of the New FIGO 2023 Staging System in Patients with Endometrial Cancer.Journal of clinical medicine · 2026Article
- Explainable machine learning for preoperative relapse prediction in molecularly stratified endometrial cancer: A single-center finnish cohort study.Computational and structural biotechnology journal · 2026Article
- Boswellic Acid Enhances Gemcitabine's Inhibition of Hypoxia-Driven Angiogenesis in Human Endometrial Cancer.Medicina (Kaunas, Lithuania) · 2025Article
- Integrative intratumoral and peritumoral radiomic model for predicting endometrial cancer grade.Oncology letters · 2025Article
- Article
- Machine learning-based radiomics model: prognostic prediction and mechanism exploration in patients with endometrial cancer.Biomarker research · 2025Article
- Article
- CircABHD2 Inhibits Malignant Progression of Endometrial Cancer by Regulating NADMolecular biotechnology · 2025Article
- Adenomyosis and endometrial cancer: determining its role as a biological contributor or incidental coexistence.BMC cancer · 2025Article
- Multiparametric MRI-based radiomics combined with 3D deep transfer learning to predict cervical stromal invasion in patients with endometrial carcinoma.Abdominal radiology (New York) · 2025Article
- Comprehensive Review of Endometrial Cancer: New Molecular and FIGO Classification and Recent Treatment Changes.Journal of clinical medicine · 2025Review
- Malignant Peritoneal Cytology Predicts Poor Prognosis and Differential Adjuvant Therapy Benefit in Endometrioid Endometrial Carcinoma: A SEER-Based Propensity Score-Matched Analysis.International journal of women's health · 2025Article
- Review
- Linoleic acid exhibits anti-proliferative and anti-invasive activities in endometrial cancer cells and a transgenic model of endometrial cancer.Cancer biology & therapy · 2024Article
- Combination of circulating tumor cells, lncRNAs and DNA methylation for the diagnosis of endometrial carcinoma.Oncology letters · 2024Article
- Management of endometrial cancer in Latin America: raising the standard of care and optimizing outcomes.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Review
- A 10-Year Retrospective Cohort Study of Endometrial Cancer Outcomes and Associations with Lymphovascular Invasion: A Single-Center Study from Germany.Diagnostics (Basel, Switzerland) · 2024Article
- KIF2A correlates with lymphovascular invasion and higher tumor stage, and can be used to predict worse prognosis in patients with endometrial carcinoma.Oncology letters · 2024Article
- Longitudinal Analysis of the Overall Survival Rates and Transitional Probabilities of Endometrial Cancer Patients: A Comprehensive Retrospective Study in Thailand.Asian Pacific journal of cancer prevention : APJCP · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is the most common gynaecologic malignancy in developed countries. The main challenge in EC management is to correctly estimate the risk of metastases at diagnosis and the risk to develop recurrences in the future. Risk stratification determines the need for surgical staging and adjuvant treatment. Detection of occult, microscopic metastases upstages patients, provides important prognostic information and guides adjuvant treatment. The molecular classification subdivides EC into four prognostic subgroups: POLE ultramutated; mismatch repair deficient (MMRd); nonspecific molecular profile (NSMP); and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.